The FY2027 President's Budget requests $207.0M for Biologics, within Health & Human Services's Biologics account. That is down 20% on the FY2026 figure of $259.3M, which is the enacted appropriation.
FY2026–FY2027
| Fiscal year | Basis | Amount |
|---|---|---|
| FY2026 | enacted | $259.3M |
| FY2027 | request | $207.0M |
Bases are separate columns and are never summed into one figure.
Health & Human Services discretionary budget authority
From the OMB Public Budget Database — clean, summable, and the figure to cite for an agency total. It is the whole of Health & Human Services's discretionary request, not a total of the parsed lines above, and this page never adds the two together.
What this funds
Ensures the safety, purity, potency, and effectiveness of biological products-including vaccines, allergenics, blood and blood products, and cell, tissue, and gene therapies-through the Center for Biologics Evaluation and Research.
Extracted from Food and Drug Administration, p. 12. Verbatim; nothing here is paraphrased.
Ask this budget line
Answers come from the figures on this page and nothing else. These dollars are parsed from Health & Human Services's Congressional Justification and are approximate — confirm anything that matters against the cited page.
This page carries the budget justification only. Contract obligations live at hitchintel.com/vendors; open solicitations at hitchintel.com/opportunities.